Treatment of Dwarfism with Recombinant Human Insulin-like Growth Factor-1

Overview

Journal Dtsch Arztebl Int

Specialties General Medicine
Public Health

Date 2009 Dec 1

PMID 19946434

Citations 12

Authors

Michael B Ranke

Joachim Wolfle

Dirk Schnabel

Markus Bettendorf

Affiliations

Soon will be listed here.

Abstract

Background: The growth hormone-IGF (insulin-like growth factor) system plays a central role in hormonal growth regulation. Recombinant human (rh) growth hormone (GH) has been available since the late 1980s for replacement therapy in GH-deficient patients and for the stimulation of growth in patients with short stature of various causes. Growth promotion by GH occurs in part indirectly through the induction of IGF-1 synthesis. In primary disturbances of IGF-1 production, short stature can only be treated with recombinant human IGF-1 (rhIGF-1). rhIGF-1 was recently approved for this indication but can also be used to treat other conditions.

Methods: Selective review of the literature on IGF-1 therapy, based on a PubMed search.

Results And Conclusion: In children with severe primary IGF-1 deficiency (a rare condition whose prevalence is less than 1:10,000), the prognosis for final height is very poor (ca. 130 cm), and IGF-1 therapy is the appropriate form of pathophysiologically based treatment. There is no alternative treatment at present. The subcutaneous administration of IGF-1 twice daily in doses of 80 to 120 microg/kg accelerates growth and increases final height by 12 to 15 cm, according to current data. There is, however, a risk of hypoglycemia, as IGF-1 has an insulin-like effect. As treatment with IGF-1 is complex, this new medication should only be prescribed, for the time being, by experienced pediatric endocrinologists and diabetologists.

Citing Articles

Insulin-Like Growth Factor 1 Has the Potential to Be Used as a Diagnostic Tool and Treatment Target for Autism Spectrum Disorders.

Shen J, Liu L, Yang Y, Zhou M, Xu S, Zhang W Cureus. 2024; 16(7):e65393.

PMID: 39188438 PMC: 11346671. DOI: 10.7759/cureus.65393.

The Treatment of Growth Disorders in Childhood and Adolescence.

Woelfle J, Schnabel D, Binder G Dtsch Arztebl Int. 2023; 121(3):96-106.

PMID: 38051162 PMC: 11002441. DOI: 10.3238/arztebl.m2023.0247.

Laron Syndrome: A Tale of Two Siblings.

Das N, Tarenia S, Saha S, Gaikwad P, Hathi D, Goswami S J ASEAN Fed Endocr Soc. 2023; 38(2):124-127.

PMID: 38045665 PMC: 10692433. DOI: 10.15605/jafes.038.02.22.

Challenges in the care of individuals with severe primary insulin-like growth factor-I deficiency (SPIGFD): an international, multi-stakeholder perspective.

Backeljauw P, Andrews M, Bang P, Dalle Molle L, Deal C, Harvey J Orphanet J Rare Dis. 2023; 18(1):312.

PMID: 37805563 PMC: 10559630. DOI: 10.1186/s13023-023-02928-7.

Insulin-like growth factor 1 promotes neurological functional recovery after spinal cord injury through inhibition of autophagy via the PI3K/Akt/mTOR signaling pathway.

Zhang D, Yuan Y, Zhu J, Zhu D, Li C, Cui W Exp Ther Med. 2021; 22(5):1265.

PMID: 34594402 PMC: 8456500. DOI: 10.3892/etm.2021.10700.

References

Buckway C, Guevara-Aguirre J, PRATT K, Burren C, Rosenfeld R . The IGF-I generation test revisited: a marker of GH sensitivity. J Clin Endocrinol Metab. 2001; 86(11):5176-83. DOI: 10.1210/jcem.86.11.8019. View

Ranke M . Defining insulin-like growth factor-I deficiency. Horm Res. 2006; 65 Suppl 1:9-14. DOI: 10.1159/000090641. View

Clemmons D, Underwood L . Nutritional regulation of IGF-I and IGF binding proteins. Annu Rev Nutr. 1991; 11:393-412. DOI: 10.1146/annurev.nu.11.070191.002141. View

Sachdev D, Yee D . Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 2007; 6(1):1-12. DOI: 10.1158/1535-7163.MCT-06-0080. View

Ballard J, Baxter R, BINOUX M, Clemmons D, Drop S, Hall K . On the nomenclature of the IGF binding proteins. Acta Endocrinol (Copenh). 1989; 121(5):751-2. DOI: 10.1530/acta.0.1210751. View

Guevara-Aguirre J, Rosenbloom A, Vasconez O, Martinez V, Gargosky S, Allen L . Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency. J Clin Endocrinol Metab. 1997; 82(2):629-33. DOI: 10.1210/jcem.82.2.3743. View

Laron Z . Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab. 2004; 89(3):1031-44. DOI: 10.1210/jc.2003-031033. View

Carro E, Trejo J, Nunez A, Torres-Aleman I . Brain repair and neuroprotection by serum insulin-like growth factor I. Mol Neurobiol. 2003; 27(2):153-62. DOI: 10.1385/MN:27:2:153. View

Goddard A, Covello R, Luoh S, Clackson T, Attie K, Gesundheit N . Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group. N Engl J Med. 1995; 333(17):1093-8. DOI: 10.1056/NEJM199510263331701. View

10.

Woods K, Camacho-Hubner C, Savage M, Clark A . Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med. 1996; 335(18):1363-7. DOI: 10.1056/NEJM199610313351805. View

11.

BAXTER R . Characterization of the acid-labile subunit of the growth hormone-dependent insulin-like growth factor binding protein complex. J Clin Endocrinol Metab. 1988; 67(2):265-72. DOI: 10.1210/jcem-67-2-265. View

12.

Schwarze C, Wollmann H, Binder G, Ranke M . Short-term increments of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 predict the growth response to growth hormone (GH) therapy in GH-sensitive children. Acta Paediatr Suppl. 1999; 88(428):200-8. DOI: 10.1111/j.1651-2227.1999.tb14392.x. View

13.

Rosenfeld R . Molecular mechanisms of IGF-I deficiency. Horm Res. 2006; 65 Suppl 1:15-20. DOI: 10.1159/000090642. View

14.

Savage M, Blum W, Ranke M, Postel-Vinay M, Cotterill A, Hall K . Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome). J Clin Endocrinol Metab. 1993; 77(6):1465-71. DOI: 10.1210/jcem.77.6.7505286. View

15.

Isaksson O, Lindahl A, Nilsson A, Isgaard J . Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. Endocr Rev. 1987; 8(4):426-38. DOI: 10.1210/edrv-8-4-426. View

16.

Chernausek S, Backeljauw P, Frane J, Kuntze J, Underwood L . Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab. 2006; 92(3):902-10. DOI: 10.1210/jc.2006-1610. View

17.

Guevara-Aguirre J, Vasconez O, Martinez V, Martinez A, Rosenbloom A, Diamond Jr F . A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab. 1995; 80(4):1393-8. DOI: 10.1210/jcem.80.4.7536209. View

18.

Kato H, Faria T, STANNARD B, Roberts Jr C, LeRoith D . Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3). J Biol Chem. 1993; 268(4):2655-61. View

19.

Backeljauw P, Underwood L . Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome--a clinical research center study. GHIS Collaborative Group. J Clin Endocrinol Metab. 1996; 81(9):3312-7. DOI: 10.1210/jcem.81.9.8784089. View

20.

Laron Z, Ginsberg S, Lilos P, Arbiv M, Vaisman N . Long-term IGF-I treatment of children with Laron syndrome increases adiposity. Growth Horm IGF Res. 2006; 16(1):61-4. DOI: 10.1016/j.ghir.2005.12.001. View